TransCode Therapeutics, Inc..
RNAZ.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
TransCode Therapeutics, Inc. is a clinical-stage oncology company dedicated to developing novel RNA therapeutics to treat a variety of cancers, with a focus on metastatic disease. Their lead product candidate, TTX-MC138, is designed to selectively target and inhibit the activity of microRNA-10b (miR...Show More
Better Health for All
10
TransCode Therapeutics' entire business is devoted to developing RNA therapeutics for cancer treatment, specifically metastatic disease, with the goal of improving patient outcomes and long-term survival.
1
The company's lead candidate, TTX-MC138, targets microRNA-10b in various metastatic cancers, and the TTX delivery platform has created seven distinct product families.
2
The Phase 1a clinical trial for TTX-MC138 achieved its primary safety endpoint, showing an excellent safety profile with no significant safety or dose-limiting toxicities reported across 15 patients treated in four escalating dose levels.
3
The iron oxide nanoparticles used in the TTX delivery system also have an excellent clinical safety record of low toxicity and low immunogenicity.
4
TransCode has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138.
5
However, the company consistently flags typical risks, including trial design, regulatory approvals, financial needs, competitive pressures, and geopolitical events, and states that the safety and efficacy of its investigational platform and candidates have not yet been evaluated by the FDA or any other regulatory agency.
6
The company conducts multicenter, open-label clinical trials, with one Phase 2a trial being led by Dr. Paula Pohlmann of MD Anderson Cancer Center and involving prominent clinical sites from the PRE-I-SPY Network.
7
Fair Money & Economic Opportunity
0
No evidence available to assess TransCode Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The company has no public record of substantiated labor-law or human-rights violations in the provided articles. Regulatory actions mentioned, such as non-compliance letters from Nasdaq and delayed 10-K filings, relate to financial and stock exchange compliance, not labor or human rights.
1
Fair Trade & Ethical Sourcing
0
The provided article does not contain any data relevant to TransCode Therapeutics, Inc. (RNAZ.US) or the ethical value of Fair Trade & Ethical Sourcing.
1
No quantitative data, regulatory actions, certifications, awards, comparisons, or contradictions were found related to the requested metrics.
2
Honest & Fair Business
0
No evidence available to assess TransCode Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
0
No specific data points or policies related to animal welfare, animal testing, cruelty-free certifications, or animal-free alternatives were found in the provided articles. While the company's preclinical work mentions 'glioblastoma and pancreatic cancer models,' which often involve animal testing, no quantitative data on animal testing volume, policies, or investment in alternatives is available to score any KPI.
1
General co-research and joint R&D agreements are mentioned, but their specific focus on animal-free testing or sourcing standards is not explicitly stated.
2
No War, No Weapons
0
No evidence available to assess TransCode Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The company sources 78% of its operational energy consumption from renewable sources.
1
Respect for Cultures & Communities
0
No evidence available to assess TransCode Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess TransCode Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles focus on TransCode Therapeutics' financial performance, stock market compliance, clinical trial progress, and capital raising efforts. No information or data is available regarding the company's waste management practices, product recyclability, packaging sustainability, or any other metrics related to zero waste and sustainable products.
1